Roche Pharmaceutical Development and Sales Overview

Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Phase/study # of patients Design ■ ARM A: Lunsumio SC on either Day 1 or on Days 1 and 8 Systemic lupus erythematosus (SLE) ARM B: Fractionated (divided) dose of Lunsumio SC on Days 1 and 8 Safety Primary endpoint FPI January 2022 Status CT Identifier SC=subcutaneous Phase I N=50 NCT05155345 96 Roche Immunology

View entire presentation